Oncoinvent ASA (OSL:ONCIN)
Norway · Delayed Price · Currency is NOK 80.20
-0.80 (-0.99%)
Aug 4, 2026, 3:56 PM CET
Oncoinvent ASA Balance Sheet
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 177.6 | 133.67 | 30.1 | 196.02 | 436.65 |
Cash & Short-Term Investments | 177.6 | 133.67 | 30.1 | 196.02 | 436.65 |
Cash Growth | 32.87% | 344.15% | -84.65% | -55.11% | -39.49% |
Accounts Receivable | 0.99 | 0.45 | - | - | - |
Other Receivables | 8.72 | 8.16 | 25.8 | 16.69 | - |
Total Trade Receivables | 9.71 | 8.61 | 25.8 | 16.69 | - |
Other Current Assets | - | - | - | - | 12.4 |
Total Current Assets | 187.31 | 142.28 | 57.92 | 212.71 | 449.05 |
Net Property, Plant & Equipment | 15.58 | 26.71 | 40.81 | 21.45 | 1.19 |
Other Long-Term Assets | 2.07 | 2.03 | 4.05 | - | - |
Total Assets | 204.96 | 171.02 | 98.73 | 234.16 | 450.24 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 15.07 | 14.74 | 12.75 | 7.7 | 26.73 |
Accrued Expenses | 6.15 | 8.49 | 5.02 | 5.46 | - |
Current Portion of Leases | 2.88 | 2.71 | 3.83 | 3.19 | - |
Other Current Liabilities | 33.87 | 31.99 | 13.86 | 15.15 | 38.14 |
Total Current Liabilities | 57.96 | 57.94 | 35.46 | 31.5 | 64.87 |
Long-Term Debt | - | - | - | - | 0.94 |
Long-Term Leases | 0.68 | 4.74 | 8.35 | 8.84 | - |
Total Long-Term Liabilities | 0.68 | 4.74 | 8.35 | 8.84 | 0.94 |
Total Liabilities | 58.63 | 62.68 | 43.8 | 40.35 | 65.81 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 223.92 | 9.22 | 1.94 | 1.94 | 8.85 |
Additional Paid-in Capital | 57.42 | 735.87 | 549.55 | 544.96 | 375.58 |
Retained Earnings | -135.01 | -636.76 | -496.56 | -353.08 | - |
Total Common Shareholders' Equity | 146.33 | 108.33 | 54.93 | 193.82 | 384.43 |
Shareholders' Equity | 146.32 | 108.33 | 54.93 | 193.82 | 384.43 |
Total Liabilities & Equity | 204.96 | 171.02 | 98.73 | 234.16 | 450.24 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.55 | 7.45 | 12.17 | 12.03 | 0.94 |
Net Cash (Debt) | 174.05 | 126.22 | 17.92 | 183.99 | 435.7 |
Net Cash Growth | 37.90% | 604.25% | -90.26% | -57.77% | -39.51% |
Net Cash Per Share | 1.41 | 5.05 | 1.25 | 209.18 | 495.36 |
Book Value | 146.33 | 108.33 | 54.93 | 193.82 | 384.43 |
Book Value Per Share | 1.18 | 4.34 | 3.84 | 220.35 | 437.06 |
Tangible Book Value | 146.33 | 108.33 | 54.93 | 193.82 | 384.43 |
Tangible Book Value Per Share | 1.18 | 4.34 | 3.84 | 220.35 | 437.06 |